COMP <GO>
CRBU vs TIL // EV/EBITDA & P/E VALUATION
Caribou Biosciences Inc. (NASDAQ) VS. Instil Bio Inc. (NASDAQ) • 15-METRIC TALLY: CRBU 2
— TIL 1
■ METRIC PARITY
LAST: $0.45 (-9.07%) • MKT CAP: $47.7M
valuation
—
LAST: $6.83 (+0.52%) • MKT CAP: $46.3M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CRBU VS. TIL)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CRBU | TIL | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 11.70% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 3/9 | +1.00 | CRBU | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 19.0 | 56.4 | -37.38 | TIL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $47.7M | $46.3M | $1.4M | CRBU | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CRBU REV | TIL REV | CRBU GROSS % | TIL GROSS % | CRBU FCF | TIL FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $11.2M | $0 | — | — | -$112.4M | -$36.6M |
| FY 2024 | $10.0M | $0 | — | — | -$143.1M | -$55.7M |
| FY 2023 | $34.5M | $0 | — | — | -$93.3M | -$82.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CRBU // BETA —
TIL // BETA —